Chondrofix Osteochondral Allograft Prospective Study

Sponsor
Zimmer Orthobiologics, Inc. (Industry)
Overall Status
Terminated
CT.gov ID
NCT01410136
Collaborator
(none)
29
5
1
35
5.8
0.2

Study Details

Study Description

Brief Summary

The overall study objective is to evaluate Chondrofix Osteochondral Allograft ("Chondrofix") for the repair of osteochondral lesions in the knee. This includes, but is not limited to primary cartilage lesion repair and revision of failed prior cartilage repair treatments. The study hypothesis is that Chondrofix Allograft will provide pain relief and functional improvement as demonstrated by a comparative analysis of baseline clinical evaluations at 24 months of follow-up.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Chondrofix Osteochondral Allograft
N/A

Detailed Description

Knee cartilage injuries are a major cause of pain and functional impairment in young to middle age adults and can lead to progressive joint degeneration. In response to challenges with current cartilage repair options, Chondrofix Allograft was developed as an off-the-shelf treatment option adding to the variety of cartilage reparation offerings.

This study is a multicenter, prospective, post-market clinical outcomes study designed to assess the clinical outcomes of Chondrofix Allograft used in the treatment of both primary and revision cartilage repair cases. Study design includes up to 6 qualified investigational sites with 50 subjects enrolled across all centers during an 18 month enrollment period. Study subjects will be followed postoperatively for 5 years. The Investigators who are responsible for the conduct of this study in compliance with this protocol will be orthopedic surgeons who are skilled in the techniques of articular cartilage repair.

Study Design

Study Type:
Interventional
Actual Enrollment :
29 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Post Market Study to Evaluate the Chondrofix® Osteochondral Allograft Utilized for Treatment of Subjects With Cartilage Lesions in the Knee
Study Start Date :
Apr 1, 2011
Actual Primary Completion Date :
Mar 1, 2014
Actual Study Completion Date :
Mar 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Other: Chondrofix

Subjects with one or two confirmed knee articular cartilage lesion(s) each less than 8cm2, of the femoral condyle or trochlear groove

Procedure: Chondrofix Osteochondral Allograft
Allogeneic, cylindrical, decellularized, osteochondral graft composed of hyaline cartilage and bone
Other Names:
  • Chondrofix
  • Outcome Measures

    Primary Outcome Measures

    1. KOOS Subscale [24 Months]

      The overall mean change from baseline to 24 months in the KOOS Pain and KOOS Function in Daily Living (ADL) subscale scores.

    Secondary Outcome Measures

    1. X-ray & MRI Evaluation [Baseline and 1.5, 3, 6, 12, 24, & 60 months]

    2. IKDC Knee Examination [Baseline & 1.5, 3, 6, 12, 24, & 60 months]

    3. Subject Reported Questionnaires [Baseline and 1.5, 3, 6, 12, 24, 36, 48, and 60 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    Generally, the following inclusion criteria must be met, however, this is not a complete list.

    • Male and non-pregnant female subjects between 18 and 70 years; subject must be skeletally mature

    • If female, subjects are not pregnant at time of surgery and do not plan on becoming pregnant during the first 24 months of the study

    • Up to two (2) cartilage lesion(s), each measuring less than 8 cm2, of the femoral condyle or trochlear groove of the knee

    • Localized knee pain unresponsive to conservative treatment (e.g., medication, bracing, physical therapy) and/or previous surgical intervention

    Exclusion Criteria:

    Generally, if a potential participant meets any of the following criteria, they will not be eligible for this study. Additionally, more criteria will be evaluated to confirm eligibility as this list is not a complete list of criteria.

    • Concurrent participation in another clinical trial

    • Cartilage lesion location is such that the implanted graft(s) will not be adequately shouldered

    • Bipolar articular cartilage involvement (or kissing lesions) of the ipsilateral compartment (i.e., > than ICRS Grade 2 on the opposing articular surface)

    • Is receiving pain medication other than NSAIDs or acetaminophen for conditions unrelated to the index knee condition

    • Subject had any other cartilage repair procedure other than debridement performed in conjunction with or 6 months prior to implantation of a Chondrofix Osteochondral Allograft

    • Prior or concurrent total meniscectomy of the index knee

    • Uncorrected mal-alignment of the index knee

    • Have smoked or used nicotine products within the past 6 months

    • Body Mass Index > 35 (BMI=kg/m2)

    • Has any contraindications for MRI

    • Requires any of the following concomitant procedures performed in conjunction with or has had performed within 6 months prior to implantation of a Chondrofix Allograft: distal realignment, high tibial osteotomy, ligament reconstruction, and/or patellar realignment procedure

    • Septic or reactive arthritis or systemic disease (e.g., rheumatoid arthritis, gout or prior history of gout or pseudo gout)

    • Sickle cell disease, hemochromatosis, or autoimmune disease

    • Unstable cardiovascular, renal, hepatic, endocrine and/or pulmonary disease, cancer or uncontrolled diabetes

    • HIV or other immune-deficient state including subject on immunosuppressant therapies

    • Deficiency limiting ability to perform an objective functional assessment of the operative knee or an inability to adhere to a post-operative rehabilitation protocol

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Plancher Orthopaedics and Sports Medicine Cos Cob Connecticut United States 06807
    2 The Orthopaedic Group, LLC New Haven Connecticut United States 06511
    3 Orthopaedic Research Foundation, Inc. Greenwood Indiana United States 46143
    4 Cartilage Repair Center, Brigham and Women's Hospital Chestnut Hill Massachusetts United States 02467
    5 Specialized Orthopaedics and Sports Medicine Columbus Ohio United States 43215

    Sponsors and Collaborators

    • Zimmer Orthobiologics, Inc.

    Investigators

    • Study Chair: Nikesha N Harrington, Zimmer Orthobiologics, Inc.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Zimmer Orthobiologics, Inc.
    ClinicalTrials.gov Identifier:
    NCT01410136
    Other Study ID Numbers:
    • CSU2010-14B
    First Posted:
    Aug 4, 2011
    Last Update Posted:
    Aug 11, 2014
    Last Verified:
    Aug 1, 2014

    Study Results

    No Results Posted as of Aug 11, 2014